Research programme: recombinant fusion proteins - Trojantech

Drug Profile

Research programme: recombinant fusion proteins - Trojantech

Alternative Names: Antennapedia Mastermind; Antennapedia Numb; Antennapedia p21; Antennapedia p53; ANTP Notch; ANTP p21; ANTP p53; NTP Mastermind; TR 1; TR 2; TR 3; TR 4

Latest Information Update: 22 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Trojantec
  • Class Antineoplastics; Peptides; Recombinant fusion proteins; Transcription factors; Tumour suppressor proteins
  • Mechanism of Action Apoptosis stimulants; Cell cycle stimulants; Transcription factor stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Apr 2016 Pharmacodynamic data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 16 Apr 2015 TR 1 licensed to Sellas Life Sciences Group
  • 15 Apr 2015 Sellas Life Sciences Group plan a phase I trial for TR 1 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top